NC
IOVA icon

NinePointTwo Capital’s Iovance Biotherapeutics IOVA Stock Holding History

NinePointTwo Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,933
Closed -$231K – 283
2023
Q2 		$231K Buy
+32,933
New +$236K 0.09% 169
2023
Q1 		– Sell
-39,969
Closed -$255K – 280
2022
Q4 		$255K Buy
+39,969
New +$312K 0.11% 58

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NinePointTwo Capital's IOVA Position: Q3 2023 in Review

NinePointTwo Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 32,933 shares — an estimated $231K sold.

NinePointTwo Capital first reported a position in IOVA in Q4 2022 and held it in 2 quarters. The position peaked at $255K in Q4 2022. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

  • NinePointTwo Capital reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 32,933 Iovance Biotherapeutics shares in Q3 2023, an estimated $231K.
  • NinePointTwo Capital first reported a position in Iovance Biotherapeutics in Q4 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Iovance Biotherapeutics position peaked at $255K in Q4 2022.
  • 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.